Major pharmaceutical companies have begun to pay top dollar for biotech companies with promising pipelines, and venture capitalists have poured money into early-stage biotech companies, lessening the importance of private equity groups for funding in the life sciences. As a result, mergers and acquisitions are replacing IPOs as the preferred "exit strategy" for investors in startup firms.

Related Summaries